Will Zelnorm Tip The Scales To Increased Drug Safety Oversight Thru PDUFA?
Executive Summary
Novartis' suspension of marketing of Zelnorm could add momentum to efforts to attach drug safety reform language to the Prescription Drug User Fee Act reauthorization legislation